Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 311 clinical trials
Sulodexide, VESSEL®, for the Prevention of Recurrent Venous Thromboembolism (The Jason Study) (Jason)

thromboembolism of the lower extremity (proximal deep vein thrombosis with or without pulmonary embolism) (VTE). Patients were randomized to receive three different treatment: Sulodexide 250 mg BIS in die

deep vein thrombosis
venous thromboembolism
pulmonary embolism
clot
thrombosis
  • 0 views
  • 25 Feb, 2022
  • 1 location
Using a Real-Time Risk Prediction Model to Predict Pediatric Venous Thromboembolism (VTE) Events

The study will evaluate the effectiveness of a novel, real-time risk prediction model for identifying pediatric patients at risk for developing in-hospital blood clots (or venous thromboembolism

clot
venous thromboembolism
blood clot
thromboembolism
  • 0 views
  • 06 Mar, 2022
  • 1 location
Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in High-Risk Patients With Provoked Venous Thromboembolism

Design: U.S.-based, single-center, randomized placebo-controlled trial. Brief Treatment Description: Low-intensity apixaban (2.5mg twice daily) for extended-duration secondary prevention of VTE after initial treatment for provoked VTE. Purpose: To establish the safety and efficacy of low-intensity apixaban versus placebo for extended prevention of recurrence after provoked VTE in patients with at …

infarct
thrombosis
heart failure
secondary prevention
dvts
  • 0 views
  • 11 Jul, 2021
  • 1 location
Left Atrial Appendage CLOSURE for the Prevention of Thromboembolisms in Patients Undergoing Aortic Bioprosthesis Surgery

The primary purpose of the LAA-CLOSURE trial is to assess the efficacy and safety of surgical closure of LAA in patients undergoing aortic valve replacement. This randomized, prospective, open-label international multicenter trial will enroll 1040 patients undergoing aortic valve replacement with CHA2DS2-VASC score 2 but without an indication for anticoagulation …

coronary artery bypass graft
aortic valve replacement
heart disease
  • 0 views
  • 10 May, 2021
  • 4 locations
Apixaban for Extended Anticoagulation (APIDULCIS) (APIDULCIS)

The study aims at optimizing the long-term and extended management of patients with a first episode of venous thromboembolism (proximal deep vein thrombosis with or without pulmonary embolism

deep vein thrombosis
venous thromboembolism
pulmonary embolism
clot
thrombosis
  • 14 views
  • 14 Feb, 2022
  • 1 location
Swedish Multicenter Trial of Outpatient Prevention of Leg Clots (StopLegClots)

Lower limb immobilization is associated with high risk of complications, i.e. venous thromboembolism (VTE) and failed healing. Pharmacoprophylaxis of VTE is in leg-immobilized patients, however

intermittent pneumatic compression
venous thromboembolism
clot
ankle fracture
fracture treatment
  • 4 views
  • 26 Apr, 2022
  • 1 location
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE (MAGNOLIA)

This is a Phase 3, multicenter, open-label, blinded endpoint study to evaluate the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding in patients

deep vein thrombosis
venous thromboembolism
pulmonary embolism
clot
thrombosis
  • 0 views
  • 19 Apr, 2022
  • 1 location
A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE (ASTER)

This is a Phase 3,multicenter, randomized, open-label, blinded endpoint evaluation study comparing the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and

  • 0 views
  • 15 Jun, 2022
  • 3 locations
A Performance Evaluation of the LumiraDx Point Of Care D-dimer Assay (EMBOL1)

In patients with symptoms of Venous Thromboembolism (VTE) (mainly deep vein thrombosis (DVT) or pulmonary embolism (PE)), the study will evaluate the agreement between the D-Dimer measurements

deep vein thrombosis
venous thromboembolism
pulmonary embolism
clot
thrombosis
  • 7 views
  • 16 Jun, 2022
  • 5 locations
Lovenox 30 mg Twice Daily (BID) Versus 40 mg Once Daily (QD)

The risk of developing a blood clot occurs in up to 60% of all critical care patients. Many times enoxaparin (or Lovenox) is given to patients who are at a higher risk of developing clots in their legs or lungs. There are two standard doses of enoxaparin that are recommended …

enoxaparin
lovenox
critical illness
clot
blood clot
  • 31 views
  • 02 May, 2022
  • 1 location